The estimated Net Worth of Neil Herskowitz is at least $408 Tisíc dollars as of 6 May 2021. Mr. Herskowitz owns over 2,500 units of Checkpoint Therapeutics Inc stock worth over $297,740 and over the last 12 years he sold CKPT stock worth over $0. In addition, he makes $110,002 as Independent Director at Checkpoint Therapeutics Inc.
Neil has made over 15 trades of the Checkpoint Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of CKPT stock worth $9,975 on 6 May 2021.
The largest trade he's ever made was buying 10,000 units of Checkpoint Therapeutics Inc stock on 25 February 2020 worth over $93,100. On average, Neil trades about 1,335 units every 79 days since 2012. As of 6 May 2021 he still owns at least 134,724 units of Checkpoint Therapeutics Inc stock.
You can see the complete history of Mr. Herskowitz stock trades at the bottom of the page.
Neil Herskowitz serves as Independent Director of the Company. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978. Based on Mr. Herskowitz’s financial industry experience and in-depth understanding of our business, the Board of Directors believes that Mr. Herskowitz has the appropriate set of skills to serve as a member of the Board.
As the Independent Director of Checkpoint Therapeutics Inc, the total compensation of Neil Herskowitz at Checkpoint Therapeutics Inc is $110,002. There are 4 executives at Checkpoint Therapeutics Inc getting paid more, with James Oliviero having the highest compensation of $2,308,250.
Neil Herskowitz is 63, he's been the Independent Director of Checkpoint Therapeutics Inc since 2015. There are 1 older and 8 younger executives at Checkpoint Therapeutics Inc. The oldest executive at Checkpoint Therapeutics Inc is Lindsay Rosenwald, 65, who is the Director.
Neil's mailing address filed with the SEC is 95 SAWYER ROAD, SUITE 110, , WALTHAM, MA, 02453.
Over the last 8 years, insiders at Checkpoint Therapeutics Inc have traded over $1,535,168 worth of Checkpoint Therapeutics Inc stock and bought 200,000 units worth $356,000 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss a James F Iii Oliviero. On average, Checkpoint Therapeutics Inc executives and independent directors trade stock every 94 days with the average trade being worth of $93,898. The most recent stock trade was executed by James F Iii Oliviero on 26 June 2024, trading 24,610 units of CKPT stock currently worth $50,451.
checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
Checkpoint Therapeutics Inc executives and other stock owners filed with the SEC include: